ArticleBlood2018
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.
Abstract readLetter
In one paragraph
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.Journal of hematology & oncology · 2026Trial
- The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.BMC cancer · 2022Trial
- Sequential RNA polymerase II activation drives human hematopoiesis.Cell reports · 2026Article
- Mutational Spectrum and Clinical Outcomes of Myelodysplastic/Myeloproliferative Neoplasms: A Single-Institution Study in Korea with Emphasis onJournal of clinical medicine · 2025Article
- Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.International journal of molecular sciences · 2024Article
- Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape.International journal of molecular sciences · 2023Review
- Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.Blood cancer journal · 2023Article
- Sex Differences in the Spectrum of Clonal Hematopoiesis.HemaSphere · 2023Article
- Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- A comprehensive genome-wide analysis of long non-coding RNA and mRNA expression profiles of JAK2V617F-positive classical myeloproliferative neoplasms.Bioengineered · 2021Article
- Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted.Leukemia · 2021Article
- Canonical Wnt: a safeguard and threat for erythropoiesis.Blood advances · 2021Review
- Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms.EJHaem · 2021Review
- Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.British journal of haematology · 2021Article
- Development of a myelodysplastic/myeloproliferative neoplasm-unclassifiable in a patient with acute myeloid leukemia: a case report and literature review.The Journal of international medical research · 2021Review
- Myelodysplastic syndromes and overlap syndromes.Blood research · 2021Review
- Review
- Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology.International journal of molecular sciences · 2021Review
- Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.Annals of hematology · 2021Article
- MDS/MPN-Unclassifiable with t(X;17)(q28;q21) and KANSL1-MTCP1/CMC4 Fusion Gene.Cytogenetic and genome research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Prithviraj BoseDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-4343-5712
Aziz NazhaDepartment of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.
Rami S KomrokjiMalignant Hematology Program, H. Lee Moffitt Cancer Center, Tampa, FL.
Keyur P PatelDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX.
Sherry A PierceDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
Najla Al-AliMalignant Hematology Program, H. Lee Moffitt Cancer Center, Tampa, FL.
Andrew SochackiDepartment of Medicine and.
Aaron ShaverDepartment of Pathology, School of Medicine, Vanderbilt University, Nashville, TN.
Wencai MaDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX; and.
Xiaoping SuDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX; and.
Naval G DaverDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
Courtney D DiNardoDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
Guillermo Garcia-ManeroDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
Sanam LoghaviDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-8980-3202
Carlos Bueso-RamosDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX.
Hagop M KantarjianDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
Mikkael A SekeresDepartment of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.
Michael R SavonaDepartment of Medicine and.
Jaroslaw P MaciejewskiDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH.
Srdan VerstovsekDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-6912-8569
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTRANSLATIONAL RESEARCH ONCOLOGY TRAINING GRANTK12CA076917 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 1997 to 2022
$14.2MVOLT (Vanderbilt Oncology Training Program)T32CA217834 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Douglas B Johnson · 2018 to 2026
$2.7MNCI NIH HHS K12 CA076917NCI NIH HHS P30 CA016672NCI NIH HHS T32 CA217834
Abstract
PubMed holds no abstract for this paper.
Indexed as
MutationAdultAgedAged, 80 and overFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutation RateMyelodysplastic-Myeloproliferative DiseasesNeoplasmsSurvival AnalysisYoung Adult
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.